Evaluating Localized Prostate Cancer and Identifying Candidates for Focal Therapy

Urology

Volumn 72, Issue 6 SUPPL., 2008, Pages

  Sartor, A Oliver ^a   Hricak, Hedvig ^b   Wheeler, Thomas M ^c   Coleman, Jonathan ^g   Penson, David F ^d   Carroll, Peter R ^e   Rubin, Mark A ^f   Scardino, Peter T ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f WEILL CORNELL MEDICAL CENTER   (United States)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

MOLECULAR MARKER; PROSTATE SPECIFIC ANTIGEN;

ALGORITHM; ARTICLE; CANCER RISK; CANCER STAGING; CELL HETEROGENEITY; CRYOSURGERY; CYSTECTOMY; FOLLOW UP; GLEASON SCORE; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; MULTIPLE CANCER; NEEDLE BIOPSY; NOMOGRAM; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE TUMOR; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR RECURRENCE; TUMOR VOLUME; ULTRASOUND;

ALGORITHMS; BIOPSY; HUMANS; MALE; NOMOGRAMS; PATIENT SELECTION; PROGNOSIS; PROSTATIC NEOPLASMS; RISK ASSESSMENT;

EID: 57449118482     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2008.10.004     Document Type: Article

References (109)

1. Eggener S.E., Scardino P.T., Carroll P.R., et al. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol 178 (2007) 2260-2267
2. Gleason D.F. Histologic grading and clinical staging of carcinoma of the prostate. In: Tannenbaum M. (Ed). Urologic Pathology (1977), Lea & Febiger, Philadelphia 171-198
3. Anderson P.R., Hanlon A.L., Patchefsky A., et al. Perineural invasion and Gleason 7-10 tumors predict increased failure in prostate cancer patients with pretreatment PSA <10 ng/ml treated with conformal external beam radiation therapy. Int J Radiat Oncol Biol Phys 41 (1998) 1087-1092
4. Beard C.J., Chen M.H., Cote K., et al. Perineural invasion is associated with increased relapse after external beam radiotherapy for men with low-risk prostate cancer and may be a marker for occult, high-grade cancer. Int J Radiat Oncol Biol Phys 58 (2004) 19-24
5. Freedland S.J., Isaacs W.B., Platz E.A., et al. Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study. J Clin Oncol 23 (2005) 7546-7554
6. Stamey T.A., Caldwell M., McNeal J.E., et al. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?. J Urol 172 (2004) 1297-1301
7. D'Amico A.V., Chen M.H., Roehl K.A., et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351 (2004) 125-135
8. D'Amico A.V., Renshaw A.A., Sussman B., et al. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 294 (2005) 440-447
9. Epstein J.I., Walsh P.C., Carmichael M., et al. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271 (1994) 368-374
10. Goto Y., Ohori M., Arakawa A., et al. Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. J Urol 156 (1996) 1059-1063
11. Kattan M.W., Shariat S.F., Andrews B., et al. The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J Clin Oncol 21 (2003) 3573-3579
12. van Gils M.P., cornel E.B., Hessels D., et al. Molecular PCA3 diagnostics on prostatic fluid. Prostate 67 (2007) 881-887
13. Laxman B., Tomlins S.A., Mehra R., et al. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia 8 (2006) 885-888
14. Li R., Heydon K., Hammond M.E., et al. Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: an analysis of patients in Radiation Therapy Oncology Group protocol 86-10. Clin Cancer Res 10 (2004) 4118-4124
15. Pollack A., DeSilvio M., Khor L.Y., et al. Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group trial 92-02. J Clin Oncol 22 (2004) 2133-2140
16. Freedland S.J., de Gregorio F., Sacoolidge J.C., et al. Predicting biochemical recurrence after radical prostatectomy for patients with organ-confined disease using p27 expression. Urology 61 (2003) 1187-1192
17. Tomlins S.A., Rhodes D.R., Perner S., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310 (2005) 644-648
18. Mehra R., Tomlins S.A., Shen R., et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol 20 (2007) 538-544
19. Demichelis F., Fall K., Perner S., et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 26 (2007) 4596-4599
20. Clark J., Merson S., Jhavar S., et al. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene 26 (2007) 2667-2673
21. Partin A.W., Yoo J., Carter H.B., et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150 (1993) 110-114
22. Makarov D.V., Trock B.J., Humphreys E.B., et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 69 (2007) 1095-1101
23. Blute M.L., Bergstralh E.J., Partin A.W., et al. Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. J Urol 164 (2000) 1591-1595
24. Graefen M., Augustin H., Karakiewicz P.I., et al. Can predictive models for prostate cancer patients derived in the United States of America be utilized in European patients?. A validation study of the Partin tables. Eur Urol 43 (2003) 6-11
25. Penson D.F., Grossfeld G.D., Li Y.P., et al. How well does the Partin nomogram predict pathological stage after radical prostatectomy in a community based population?. Results of the Cancer of the Prostate Strategic Urological Research Endeavor. J Urol 167 (2002) 1653-1658
26. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 (1998) 969-974
27. D'Amico A.V., Moul J., Carroll P.R., et al. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 21 (2003) 2163-2172
28. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol 18 (2000) 1164-1172
29. Roach M., Lu J., Pilepich M.V., et al. Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials. Int J Radiat Oncol Biol Phys 47 (2000) 609-615
30. Mitchell J.A., Cooperberg M.R., Elkin E.P., et al. Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE. J Urol 173 (2005) 1126-1131
31. Tsai H.K., Chen M.H., McLeod D.G., et al. Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer. Cancer 107 (2006) 2597-2603
32. Cagiannos I., Karakiewicz P., Eastham J.A., et al. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol 170 (2003) 1798-1803
33. Koh H., Kattan M.W., Scardino P.T., et al. A nomogram to predict seminal vesicle invasion by the extent and location of cancer in systematic biopsy results. J Urol 170 (2003) 1203-1208
34. Ohori M., Kattan M.W., Koh H., et al. Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer. J Urol 171 (2004) 1844-1849
35. Kattan M.W., Eastham J.A., Stapleton A.M., et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90 (1998) 766-771
36. Kattan M.W., Zelefsky M.J., Kupelian P.A., et al. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol 18 (2000) 3352-3359
37. Kattan M.W., Potters L., Blasko J.C., et al. Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urology 58 (2001) 393-399
38. Kattan M.W., Zelefsky M.J., Kupelian P.A., et al. Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer. J Clin Oncol 21 (2003) 4568-4571
39. Graefen M., Karakiewicz P.I., Cagiannos I., et al. International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol 20 (2002) 3206-3212
40. Graefen M., Karakiewicz P.I., Cagiannos I., et al. Validation study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy for localized prostate cancer. J Clin Oncol 20 (2002) 951-956
41. Bianco Jr. F.J., Kattan M.W., Scardino P.T., et al. Radical prostatectomy nomograms in black American men: accuracy and applicability. J Urol 170 (2003) 73-77
42. Stephenson A.J., Scardino P.T., Eastham J.A., et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 98 (2006) 715-717
43. Zelefsky M.J., Kattan M.W., Fearn P., et al. Pretreatment nomogram predicting ten-year biochemical outcome of three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for prostate cancer. Urology 70 (2007) 283-287
44. Cooperberg M.R., Pasta D.J., Elkin E.P., et al. The University of California, San Francisco, Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 173 (2005) 1938-1942
45. Freedland S.J., Terris M.K., Csathy G.S., et al. Preoperative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade and serum prostate specific antigen. J Urol 171 (2004) 2215-2220
46. Kattan M.W., Cuzick J., Fisher G., et al. A nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent. Cancer 112 (2008) 69-74
47. Pickles T., Liu M., Berthelet E., et al. The effect of smoking on outcome following external radiation for localized prostate cancer. J Urol 171 (2004) 1543-1546
48. Amling C.L. Relationship between obesity and prostate cancer. Curr Opin Urol 15 (2005) 167-171
49. Mallah K.N., DiBlasio C.J., Rhee A.C., et al. Body mass index is weakly associated with, and not a helpful predictor of, disease progression in men with clinically localized prostate carcinoma treated with radical prostatectomy. Cancer 103 (2005) 2030-2034
50. Hall W.H., Jani A.B., Ryu J.K., et al. The impact of age and comorbidity on survival outcomes and treatment patterns in prostate cancer. Prostate Cancer Prostatic Dis 8 (2005) 22-30
51. Moore R.A. The morphology of small prostatic carcinomas. J Urol 33 (1935) 224-234
52. Greene D.R., Rogers E., Wessels E.C., et al. Some small prostate cancers are nondiploid by nuclear image analysis: correlation of deoxyribonucleic acid ploidy status and pathological features. J Urol 151 (1994) 1301-1307
53. Wise A.M., Stamey T.A., McNeal J.E., et al. Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. Urology 60 (2002) 264-269
54. Cheng L., Jones T.D., Pan C.X., et al. Anatomic distribution and pathologic characterization of small-volume prostate cancer (<0.5 ml) in whole-mount prostatectomy specimens. Mod Pathol 18 (2005) 1022-1026
55. Ohori M. Is focal therapy reasonable in patients with early stage prostate cancer (CaP)-an analysis of radical prostatectomy (RP) specimens (abstract). J Urol 173 (2006)
56. Villers A., McNeal J.E., Freiha F.S., et al. Multiple cancers in the prostate: morphologic features of clinically recognized versus incidental tumors. Cancer 70 (1992) 2313-2318
57. Rukstalis D.B., Goldknopf J.L., Crowley E.M., et al. Prostate cryoablation: a scientific rationale for future modifications. Urology 60 suppl 1 (2002) 19-25
58. Noguchi M., Stamey T.A., McNeal J.E., et al. Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: lack of significance of secondary cancers. J Urol 170 (2003) 459-463
59. McNeal J.E., Bostwick D.G., Kindrachuck R.A., et al. Patterns of progression in prostate cancer. Lancet 1 (1986) 60-63
60. Sakr W.A., Haas G.P., Cassin B.F., et al. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 150 (1993) 379-385
61. Aihara M., Wheeler T.M., Ohori M., et al. Heterogeneity of prostate cancer in radical prostatectomy specimens. Urology 43 (1994) 60-67
62. Stamey T.A., McNeal J.E., Yemoto C.M., et al. Biological determinants of cancer progression in men with prostate cancer. JAMA 281 (1999) 1395-1400
63. Rubin M.A., Mucci N.R., Manley S., et al. Predictors of Gleason pattern 4/5 prostate cancer on prostatectomy specimens: can high grade tumor be predicted preoperatively?. J Urol 165 (2001) 114-118
64. McNeal J.E., and Haillot O. Patterns of spread of adenocarcinoma in the prostate as related to cancer volume. Prostate 49 (2001) 48-57
65. Epstein J.I., Carmichael M.J., Partin A.W., et al. Small high grade adenocarcinoma of the prostate in radical prostatectomy specimens performed for nonpalpable disease: pathogenetic and clinical implications. J Urol 151 (1994) 1587-1592
66. Kulkarni G.S., Al-Azab R., Lockwood G., et al. Evidence for a biopsy derived grade artifact among larger prostate glands. J Urol 175 (2006) 505-509
67. Hodge K.K., McNeal J.E., Terris M.K., et al. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 142 (1989) 71-75
68. Roehl K.A., Antenor J.A., and Catalona W.J. Serial biopsy results in prostate cancer screening study. J Urol 167 (2002) 2435-2439
69. Presti Jr. J.C., Chang J.J., Bhargava V., et al. The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial. J Urol 163 (2000) 163-167
70. Presti Jr. J.C., O'Dowd G.J., Miller M.C., et al. Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in prostate specific antigen and age related cancer rates: results of a community multi-practice study. J Urol 169 (2003) 125-129
71. Naughton C.K., Ornstein D.K., Smith D.S., et al. Pain and morbidity of transrectal ultrasound guided prostate biopsy: a prospective randomized trial of 6 versus 12 cores. J Urol 163 (2000) 168-171
72. Singh H., canto E.I., Shariat S.F., et al. Improved detection of clinically significant, curable prostate cancer with systematic 12-core biopsy. J Urol 171 (2004) 1089-1092
73. Fleshner N., Rakovitch E., and Klotz L. Differences between urologists in the United States and Canada in the approach to prostate cancer. J Urol 163 (2000) 1461-1466
74. Eskew L.A., Bare R.L., and McCullough D.L. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol 157 (1997) 199-203
75. Gore J.L., Shariat S.F., Miles B.J., et al. Optimal combinations of systematic sextant and laterally directed biopsies for the detection of prostate cancer. J Urol 165 (2001) 1554-1559
76. Applewhite J.C., Matlaga B.R., and McCullough D.L. Results of the 5 region prostate biopsy method: the repeat biopsy population. J Urol 168 (2002) 500-503
77. Obek C., Louis P., Civantos F., et al. Comparison of digital rectal examination and biopsy results with the radical prostatectomy specimen. J Urol 161 (1999) 494-499
78. Scherr D.S., Eastham J., Ohori M., et al. Prostate biopsy techniques and indications: when, where, and how?. Semin Urol Oncol 20 (2002) 18-31
79. Pelzer A., Bektic J., Berger A.P., et al. Prostate cancer detection in men with prostate specific antigen 4-10 ng/ml using a combined approach of contrast enhanced color Doppler targeted and systematic biopsy. J Urol 173 (2005) 1926-1929
80. Lattouf J.B., Grubb III R.L., Lee S.J., et al. Magnetic resonance imaging-directed transrectal ultrasonography-guided biopsies in patients at risk of prostate cancer. BJU Int 99 (2007) 1041-1046
81. Singh A.K., Krieger A., Lattouf J.B., et al. Patient selection determines the prostate cancer yield of dynamic contrast-enhanced magnetic resonance imaging-guided transrectal biopsies in a closed 3-Tesla scanner. BJU Int 101 (2008) 181-185
82. Pepe P., and Aragona F. Saturation prostate needle biopsy and prostate cancer detection at initial and repeat evaluation. Urology 70 (2007) 1131-1135
83. Stewart C.S., Leibovich B.C., Weaver A.L., et al. Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol 166 (2001) 86-92
84. Pinkstaff D.M., Igel T.C., Petrou S.P., et al. Systematic transperineal ultrasound-guided template biopsy of the prostate: three-year experience. Urology 65 (2005) 735-739
85. Chon C.H., Lai F.C., McNeal J.E., et al. Use of extended systematic sampling in patients with a prior negative prostate needle biopsy. J Urol 167 (2002) 2457-2460
86. Borboroglu P.G., Comer S.W., Riffenburgh R.H., et al. Extensive repeat transrectal ultrasound guided prostate biopsy in patients with previous benign sextant biopsies. J Urol 163 (2000) 158-162
87. Peck S. Transperineal needle biopsy of the prostate. J Urol 107 (1972) 1025-1027
88. Igel T.C., Knight M.K., Young P.R., et al. Systematic transperineal ultrasound guided template biopsy of the prostate in patients at high risk. J Urol 165 (2001) 1575-1579
89. Bott S.R., Henderson A., Halls J.E., et al. Extensive transperineal template biopsies of prostate: modified technique and results. Urology 68 (2006) 1037-1041
90. Moran B.J., Braccioforte M.H., and Conterato D.J. Re-biopsy of the prostate using a stereotactic transperineal technique. J Urol 176 (2006) 1376-1381
91. Merrick G.S., Gutman S., Andreini H., et al. Prostate cancer distribution in patients diagnosed by transperineal template-guided saturation biopsy. Eur Urol 52 (2007) 715-723
92. Crawford E.D., Wilson S.S., Torkko K.C., et al. Clinical staging of prostate cancer: a computer-simulated study of transperineal prostate biopsy. BJU Int 96 (2005) 999-1004
93. Miller J., Perumalla C., and Heap G. Complications of transrectal versus transperineal prostate biopsy. ANZ J Surg 75 (2005) 48-50
94. Webb J.A., Shanmuganathan K., and McLean A. Complications of ultrasound-guided transperineal prostate biopsy: a prospective study. Br J Urol 72 (1993) 775-777
95. Ryan P.G., and Peeling W.B. Perineal prostatic tumour seedling after "Tru-Cut" needle biopsy: case report and review of the literature. Eur Urol 17 (1990) 189-192
96. Wang L., Hricak H., Kattan M.W., et al. Prediction of organ-confined prostate cancer: incremental value of MR imaging and MR spectroscopic imaging to staging nomograms. Radiology 238 (2006) 597-603
97. Wang L., Mullerad M., Chen H.N., et al. Prostate cancer: incremental value of endorectal MR imaging findings for prediction of extracapsular extension. Radiology 232 (2004) 133-139
98. Mullerad M., Hricak H., Wang L., et al. Prostate cancer: detection of extracapsular extension by genitourinary and general body radiologists at MR imaging. Radiology 232 (2004) 140-146
99. Hricak H., Wang L., Wei D.C., et al. The role of preoperative endorectal magnetic resonance imaging in the decision regarding whether to preserve or resect neurovascular bundles during radical retropubic prostatectomy. Cancer 100 (2004) 2655-2663
100. Wefer A.E., Hricak H., Vigneron D.B., et al. Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J Urol 164 (2000) 400-404
101. Akin O., Sala E., Moskowitz C.S., et al. Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging. Radiology 239 (2006) 784-792
102. Kitamura Y, Kaji Y, Li H, et al. Prostate cancer derived from transition zone specific findings on MR imaging. Presented at the Ninth European Symposium on Urogenital Radiology, June 15-20, 2002, Genoa, Italy.
103. Coakley F.V., Kurhanewicz J., Lu Y., et al. Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging. Radiology 223 (2002) 91-97
104. Zakian K.L., Sircar K., Hricak H., et al. Correlation of proton MR spectroscopic imaging with Gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology 234 (2005) 804-814
105. Shukla-Dave A., Hricak H., Kattan M.W., et al. The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: an initial analysis. BJU Int 99 (2007) 786-793
106. Parivar F., Hricak H., Shinohara K., et al. Detection of locally recurrent prostate cancer after cryosurgery: evaluation by transrectal ultrasound, magnetic resonance imaging, and three-dimensional proton magnetic resonance spectroscopy. Urology 48 (1996) 594-599
107. Kalbhen C.L., Hricak H., Shinohara K., et al. Prostate carcinoma: MR imaging findings after cryosurgery. Radiology 198 (1996) 807-811
108. Rouviere O., Souchon R., Salomir R., et al. Transrectal high-intensity focused ultrasound ablation of prostate cancer: effective treatment requiring accurate imaging. Eur J Radiol 63 (2007) 317-327
109. Hindley J., Gedroyc W.M., Regan L., et al. MRI guidance of focused ultrasound therapy of uterine fibroids: early results. AJR Am J Roentgenol 183 (2004) 1713-1719